Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LACTIN-V for Prevention of Bacterial Vaginosis Recurrence
NCT02766023Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jun 2016
- Primary completion
- Feb 2019
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in bacterial vaginosis (BV) comparing LACTIN-V with Placebo (2 arms). Primary endpoints: Proportion of Participants With a Positive BV Diagnosis at 12 weeks and Proportion of Participants Reporting Product-related Adverse Events (AEs) and Serious Adverse Events (SAEs) at 24 weeks. Started Jun 2016; status: completed.
02
Drugs
lactobacillus crispatus ctv-05
03
Conditions
bacterial vaginosis (BV)
Beyond the preview
Go deeper on NCT02766023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02766023.